The EDC is live today — see what ships now
All studies
NCT07277231From ClinicalTrials.govRecruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia

  • Chronic Lymphocytic Leukemia

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
BeOne Medicines
Enrolment target
500
Started
22 January 2026
Main results due
February 2031
Study sites
115
Registry updated
28 September 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
* Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
* Measurable disease by Computer Tomography/Magnetic Resonance Imaging
* Adequate bone marrow and organ function

Exclusion Criteria:

* Previous systemic treatment for CLL
* Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
* Known central nervous system involvement
* History of confirmed progressive multifocal leukoencephalopathy (PML)
* Uncontrolled hypertension or clinically significant cardiovascular disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Study sites(115)

  • City of Hope National Medical Center

    Duarte, California, United States

    Recruiting

  • Chao Family Comprehensive Cancer Center

    Orange, California, United States

    Recruiting

  • Stanford Cancer Institute

    Palo Alto, California, United States

    Recruiting

  • Rocky Mountain Cancer Centers (Williams) Usor

    Aurora, Colorado, United States

    Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, United States

    Recruiting

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida, United States

    Recruiting

  • Moffitt Cancer Center

    Tampa, Florida, United States

    Recruiting

  • Northwestern University

    Chicago, Illinois, United States

    Recruiting

  • Midwestern Regional Medical Center

    Zion, Illinois, United States

    Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, United States

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota, United States

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, United States

    Recruiting

  • Columbia University Medical Center

    New York, New York, United States

    Recruiting

  • Atrium Health Levine Cancer Institute (Lci)

    Charlotte, North Carolina, United States

    Recruiting

  • Duke University Medical Center

    Durham, North Carolina, United States

    Recruiting

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon, United States

    Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania, United States

    Recruiting

  • Texas Oncology Tyler

    Tyler, Texas, United States

    Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah, United States

    Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, United States

    Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

    Recruiting

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

    Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

    Recruiting

  • Genesiscare North Shore

    St Leonards, New South Wales, Australia

    Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

    Recruiting

  • Monash Health

    Clayton, Victoria, Australia

    Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia

    Recruiting

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia

    Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia

    Recruiting

  • Instituto Dor de Pesquisa E Ensino Distrito Federal

    Brasília, Brazil

    Recruiting

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

    Porto Alegre, Brazil

    Recruiting

  • Ensino E Terapia de Inovacao Clinica Amo Etica

    Salvador, Brazil

    Recruiting

  • Instituto Dor de Pesquisa E Ensino Sao Paulo

    São Paulo, Brazil

    Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil

    Recruiting

  • Bc Cancer Victoria

    Victoria, British Columbia, Canada

    Recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

    Recruiting

  • Ciusss Nim Hscm

    Montreal, Quebec, Canada

    Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada

    Recruiting

  • Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)

    Québec, Quebec, Canada

    Recruiting

  • Ciusss de Lestrie Chus

    Sherbrooke, Quebec, Canada

    Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

    Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

    Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

    Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

    Active, not recruiting

  • Sun Yat Sen University Cancer Center Huangpu Branch

    Guangzhou, Guangdong, China

    Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

    Recruiting

  • Guizhou Provincial Peoples Hospital

    Guiyang, Guizhou, China

    Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

    Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

    Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

    Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

    Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

    Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

    Recruiting

  • The Second Affiliated Hospital of Xian Jiaotong University

    Xi'an, Shaanxi, China

    Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China

    Recruiting

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

    Recruiting

  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

    Chengdu, Sichuan, China

    Recruiting

  • Institute of Hematology and Hospital of Blood Disease

    Tianjin, Tianjin Municipality, China

    Recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

    Recruiting

Showing 60 of 115 sites — filter to narrow it down. 114 of the 115 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07277231. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acal | Trialion